Publication: Vitamin D Endocrine System and COVID-19
dc.contributor.author | Bouillon, Roger | |
dc.contributor.author | Quesada-Gomez, José Manuel | |
dc.contributor.authoraffiliation | [Bouillon,R] Laboratory of Clinical and Experimental Endocrinology, Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium. [Quesada-Gomez,JM] Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía, Universidad de Córdoba, Fundación Progreso y Salud, Córdoba, Spain. [Quesada-Gomez,JM] CIBER de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain. | |
dc.date.accessioned | 2022-05-20T12:31:02Z | |
dc.date.available | 2022-05-20T12:31:02Z | |
dc.date.issued | 2021-12 | |
dc.description.abstract | Preclinical data strongly suggest that the vitamin D endocrine system (VDES) may have extraskeletal effects. Cells of the immune and cardiovascular systems and lungs can express the vitamin D receptor, and overall these cells respond in a coherent fashion when exposed to 1,25-dihydroxyvitamin D, the main metabolite of the VDES. Supplementation of vitamin D-deficient subjects may decrease the risk of upper respiratory infections. The VDES also has broad anti-inflammatory and anti-thrombotic effects, and other mechanisms argue for a potential beneficial effect of a good vitamin D status on acute respiratory distress syndrome, a major complication of this SARS-2/COVID-19 infection. Activation of the VDES may thus have beneficial effects on the severity of COVID-19. Meta-analysis of observational data show that a better vitamin D status decreased the requirement of intensive care treatment or decreased mortality. A pilot study in Cordoba indicated that admission to intensive care was drastically reduced by administration of a high dose of calcifediol early after hospital admission for COVID-19. A large observational study in Barcelona confirmed that such therapy significantly decreased the odds ratio (OR) of mortality (OR = 0.52). This was also the conclusion of a retrospective study in five hospitals of Southern Spain. A retrospective study on all Andalusian patients hospitalized because of COVID-19, based on real-world data from the health care system, concluded that prescription of calcifediol (hazard ratio [HR] = 0.67) or vitamin D (HR = 0.75), 15 days before hospital admission decreased mortality within the first month. In conclusion, a good vitamin D status may have beneficial effects on the course of COVID-19. This needs to be confirmed by large, randomized trials, but in the meantime, we recommend (rapid) correction of 25 hydroxyvitamin D (25OHD) deficiency in subjects exposed to this coronavirus. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research. | es_ES |
dc.description.version | Yes | es_ES |
dc.identifier.citation | Bouillon R, Quesada-Gomez JM. Vitamin D Endocrine System and COVID-19. JBMR Plus. 2021 Nov 17;5(12):e10576. | es_ES |
dc.identifier.doi | 10.1002/jbm4.10576 | es_ES |
dc.identifier.essn | 2473-4039 | |
dc.identifier.pmc | PMC8674769 | |
dc.identifier.pmid | 34950831 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10668/3660 | |
dc.journal.title | JBMR plus | |
dc.language.iso | en | |
dc.page.number | 13 p. | |
dc.publisher | Wiley-Blackwell Publishing | es_ES |
dc.relation.publisherversion | https://asbmr.onlinelibrary.wiley.com/doi/10.1002/jbm4.10576 | es_ES |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.accessRights | open access | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Vitamin D | es_ES |
dc.subject | Calcifediol | es_ES |
dc.subject | COVID-19 | es_ES |
dc.subject | Mortality | es_ES |
dc.subject | Acute respiratory distress syndrome | es_ES |
dc.subject | Intensive care treatment | es_ES |
dc.subject | Vitamina D | es_ES |
dc.subject | Mortalidad | es_ES |
dc.subject | Síndrome de dificultad respiratoria | es_ES |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Polycyclic Compounds::Steroids::Cholestanes::Cholestenes::Cholecalciferol::Hydroxycholecalciferols::Calcifediol | es_ES |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Polycyclic Compounds::Steroids::Secosteroids::Vitamin D | es_ES |
dc.subject.mesh | Medical Subject Headings::Technology and Food and Beverages::Food and Beverages::Food::Dietary Supplements | es_ES |
dc.subject.mesh | Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Patient Care::Critical Care | es_ES |
dc.subject.mesh | Medical Subject Headings::Anatomy::Endocrine System | es_ES |
dc.subject.mesh | Medical Subject Headings::Diseases::Respiratory Tract Diseases::Lung Diseases::Respiratory Distress Syndrome, Adult | es_ES |
dc.subject.mesh | Medical Subject Headings::Anatomy::Cardiovascular System | es_ES |
dc.subject.mesh | Medical Subject Headings::Health Care::Health Services Administration::Patient Care Management::Delivery of Health Care | es_ES |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Inflammatory Agents | es_ES |
dc.subject.mesh | Medical Subject Headings::Diseases::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections | es_ES |
dc.subject.mesh | Medical Subject Headings::Organisms::Viruses::RNA Viruses::Nidovirales::Coronaviridae::Coronavirus::SARS Virus | es_ES |
dc.title | Vitamin D Endocrine System and COVID-19 | es_ES |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Bouillon_VitaminDEndocrine.pdf
- Size:
- 1 MB
- Format:
- Adobe Portable Document Format
- Description:
- Artículo original